Industry Insights

• 
  Has the booming PD-1 inhibitor reached its limit? Krebs Qin
  October 18, 2024
  In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
• 
  Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
  October 18, 2024
  Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
• 
  What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
  October 18, 2024
  On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.

• 
  Globalization of drugs -A Double-Edged Sword with Room for Improvement Shruti Talashi
  November 20, 2024
  The pharmaceutical business has been experiencing globalization for a number of years due to factors such as the growing need for cutting-edge treatments in developing nations, the need for drug companies to cut costs, and the rising difficulties in recru

• 
  AI in Pharmacovigilance: Predicting & Preventing Drug Risks Nurah Ekhlaque
  November 19, 2024
• 
  Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases PharmaSources
  October 15, 2024
• 
  Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
  October 15, 2024
  Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.

• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
  Mugwort, also known as fragrant mugwort or Artemisia argyi, is a herbaceous plant belonging to the Compositae family.
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024
• 
  Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives Xiaomichong
  July 19, 2024

• 
  What companies are developing CNS drugs in China? ChatGTP/PharmaSources
  November 08, 2023
  Several pharmaceutical and biotechnology companies in China are actively involved in the research and development of Central Nervous System (CNS) drugs.